JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT Journal

publication venue for

Long-term Efficacy of up to 4 Years of Therapy with Bimekizumab in Patients with Plaque Psoriasis after Switching from Adalimumab, Ustekinumab, or Secukinumab to BE BRIGHT and BE RADIANT 2025
Long-term efficacy of up to 4 years of therapy with bimekizumab in patients with plaque psoriasis after switching from adalimumab, ustekinumab, or secukinumab in BE BRIGHT and BE RADIANT 2025
Dupilumab with topical corticosteroids results in rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across all anatomic regions over 52 weeks 2021
Dupilumab for Adolescents With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 3, Randomized, Double-Blinded Trial 2019
Factors affecting response to secukinumab in plaque psoriasis patients: a pooled analysis of FIXTURE and CLEAR 2019
Persistent reduction of response to secukinumab is uncommon in plaque psoriasis patients: a pooled analysis of FIXTURE and CLEAR 2019

International Standard Serial Number (ISSN)

1610-0379

Electronic International Standard Serial Number (EISSN)

1610-0387